Annette Boyle
Staff Writer at BioWorld
Editor at BioWorld MedTech
Experienced medical writer and continuing medical education consultant with Yale MBA.
Articles
-
4 days ago |
bioworld.com | Annette Boyle
ADA 2025Two new options presented at ADA for early diagnosis of T1DClassically, the diagnosis of type 1 diabetes comes after a patient presents with unexplained weight loss, extreme thirst and frequent urination and a lab test reveals off-the-charts blood glucose levels.
-
4 days ago |
bioworld.com | Annette Boyle
ADA 2025AID system improves glycemic control in pregnancyPregnant women with type 1 diabetes who used a hybrid closed loop automated insulin delivery system averaged more than three additional hours per day in their recommended glucose range than those who managed their diabetes with insulin injections or non-automated pump systems, a study presented at the 85th Scientific Sessions of the American Association in Chicago demonstrated.
-
5 days ago |
bioworld.com | Annette Boyle
Home » Hearts break as Carmat faces insolvency BioWorld briefs for June 23, 2025. BioWorld MedTech briefs for June 20, 2025. To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small... BioWorld Asia briefs for June 17, 2025 With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
-
5 days ago |
bioworld.com | Annette Boyle
Fractyl pursues dual track to cure T2 diabetesAt the American Diabetes Association 85th Scientific Sessions in Chicago June 20-23, Fractyl Health Inc. presented results from two studies evaluating very different approaches to treating – and possibly curing – type 2 diabetes. BioWorld MedTech Clinical American Diabetes Association Diabetes Obesity
-
1 week ago |
bioworld.com | Annette Boyle
Caris settles IPO at $21, trading starts at $28Despite raising the price of its IPO twice, Caris Life Sciences Inc. left money on the table with a 33% increase in price as soon as trading commenced on the Nasdaq, though no one is squawking about raising nearly $500 million. The cancer diagnostics company initially priced its IPO at $16 to $18, then raised it to $19 to $20, before closing on a price of $21 per share.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 102
- Tweets
- 111
- DMs Open
- No
Does dude doing the play-by-play on @WElite8 on ABC think he's on the radio? Can he breathe a little more so the women can add the insight that makes it interesting? ESPN is so much better
“The cost of apathy is life, but the price of life is as small as an act of kindness. I am a life preserved by the kindness that was offered to me by others when I could not produce kindness for myself.” Harry Miller @h_miller76
RT @ananavarro: Oof! This was hard to watch. I’ve known @chefjoseandres for many years and am proud to call him a friend. He’s seen awful…
